Krystal to present KB407 CORAL-1 interim cystic fibrosis data at ATS 2026
Krystal Biotech presented data on KB407, KB409/KB410, KB707 for Cystic fibrosis, primary ciliary dyskinesia, solid tumors at a medical meeting on Apr 30, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Krystal Biotech, Inc. KRYS
- Drug
- KB407, KB409/KB410, KB707
- For
- Cystic fibrosis, primary ciliary dyskinesia, solid tumors
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Apr 30, 2026
- Source note
- Krystal flagged May-June scientific presentations including an ATS oral on interim CORAL-1 results for inhaled KB407 in cystic fibrosis (May 20), an ASGCT poster on PCD vectors KB409/KB410, and an ASCO poster on inhaled KB707 with pembrolizumab.
- Checked
- Checked by a person when it was added
- Source: ir.krystalbio.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KRYS headlines on this site
Krystal Biotech expects to report results from its Phase 1 study of KB407 (inhaled HSV-1 gene therapy) for Cystic fibrosis in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- KB407 interim results in cystic fibrosis · Clinical trial results (readout / topline data)
- Drug
- KB407 (inhaled HSV-1 gene therapy)
- For
- Cystic fibrosis
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 results: interim study results expected before year end 2026 (~5 patients).
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KRYS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Phase 1 study of KB707 (intratumoral) for Gorlin syndrome (basal cell carcinomas) in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- KB707 intratumoral Gorlin syndrome (OPAL-1) interim update later in 2026 · Clinical trial results (readout / topline data)
- Drug
- KB707 (intratumoral)
- For
- Gorlin syndrome (basal cell carcinomas)
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 PR (Aug 3, 2026): three Gorlin patients enrolled in OPAL-1; interim update plus development plans 'later this year'.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KRYS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
KB707 inhaled KYANITE-1 final dose-expansion cohort enrollment completion, expected in the second half of 2026 (no exact date yet). A company milestone for Krystal Biotech (KB707 (inhaled) for advanced NSCLC): a step in the program rather than a decision or a data readout.
More details
- Entry
- KB707 inhaled KYANITE-1 final dose-expansion cohort enrollment completion · Company milestone
- Drug
- KB707 (inhaled)
- For
- advanced NSCLC
- Stage
- Phase 1/2 · an early study that checks safety and takes a first look at effect
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 PR (Aug 3, 2026); updated interim results and potential registrational plans to follow in 1H 2027 (already tracked).
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KRYS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
VYJUVEK additional MAA filings incl. Switzerland and Australia in 2H 2026, expected in the second half of 2026 (no exact date yet). A company milestone for Krystal Biotech (VYJUVEK (beremagene geperpavec) for dystrophic epidermolysis bullosa): a step in the program rather than a decision or a data readout.
More details
- Entry
- VYJUVEK additional MAA filings incl. Switzerland and Australia in 2H 2026 · Company milestone
- Drug
- VYJUVEK (beremagene geperpavec)
- For
- dystrophic epidermolysis bullosa
- Stage
- Regulatory (ex-US)
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 PR (Aug 3, 2026); Spain and Italy commercial launches also expected before year end.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KRYS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Phase 1 study of KB111 for Hailey-Hailey disease in Q4 2026 (Oct–Dec) (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- UPDATE: KB111 HALITE-1 Hailey-Hailey interim results guided before year-end 2026 · Clinical trial results (readout / topline data)
- Drug
- KB111
- For
- Hailey-Hailey disease
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- existing KRYS|readout|2026-H2 KB111 HALITE-1 interim; Q2 2026 PR (Aug 3, 2026) says 'before year end' (mapped to Q4); FDA meeting to follow to enable 2027 registrational start.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KRYS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Krystal Biotech expects to report results from its Registrational (IOLITE) study of KB803 (gene therapy eye drop) for Corneal abrasions in dystrophic epidermolysis bullosa in Q4 2026 (Oct–Dec) (no exact date yet). Registrational (IOLITE) is a study designed to support approval.
More details
- Entry
- KB803 IOLITE registrational topline in DEB corneal abrasions · Clinical trial results (readout / topline data)
- Drug
- KB803 (gene therapy eye drop)
- For
- Corneal abrasions in dystrophic epidermolysis bullosa
- Stage
- Registrational (IOLITE) · a study designed to support approval
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Q2 2026 results (Aug 3, 2026): IOLITE fully enrolled in April 2026; top-line data readout guided for 4Q 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- KRYS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page